ACSS2 Inhibitors for Cancer, Alcoholism, Viral Infections

ChangeBridge: Patent Apps - Organic Chemistry (C07D)

Published September 8th, 2025

Detected March 26th, 2026

Summary

The USPTO has published a patent application (US20260085048A1) detailing novel ACSS2 inhibitors and their potential uses in treating cancer, alcoholism, and viral infections. The application was filed on September 8, 2025.

View original document View source feed page

What changed

This document is a patent application (US20260085048A1) filed with the USPTO on September 8, 2025. It describes novel ACSS2 inhibitors and methods of use for treating various conditions including cancer, alcoholism, viral infections (such as CMV), alcoholic steatohepatitis (ASH), non-alcoholic steatohepatitis (NASH), obesity, anxiety, depression, PTSD, and inflammatory/autoimmune conditions.

As this is a patent application, it does not impose direct compliance obligations on regulated entities. However, it signifies potential future developments in drug discovery and therapeutic treatments. Companies involved in pharmaceutical research and development, particularly in oncology, infectious diseases, and metabolic disorders, should be aware of this filing as it may indicate new avenues for intellectual property and product development in these areas.

Source document (simplified)

← USPTO Patent Applications

ACSS2 INHIBITORS AND METHODS OF USE THEREOF

Application US20260085048A1 Kind: A1 Mar 26, 2026

Inventors

Philippe NAKACHE, Omri EREZ, Simone BOTTI, Andreas GOUTOPOULOS, Harry FINCH

Abstract

The present invention relates to novel ACSS2 inhibitors having activity as anti-cancer therapy, treatment of alcoholism, and viral infection (e.g., CMV), composition and methods of preparation thereof, and uses thereof for treating viral infection, alcoholism, alcoholic steatohepatitis (ASH), non-alcoholic steatohepatitis (NASH), obesity/weight gain, anxiety, depression, post-traumatic stress disorder, inflammatory/autoimmune conditions and cancer, including metastatic cancer, advanced cancer, and dmg resistant cancer of various types.

CPC Classifications

C07D 231/22 A61K 31/4152 A61K 31/4155 A61K 31/4184 A61K 31/422 A61K 31/427 A61K 31/4439 A61K 31/454 A61K 31/497 A61K 31/506 A61K 45/06 A61P 3/00 A61P 25/00 A61P 29/00 A61P 31/12 A61P 35/00 A61P 37/02 C07D 231/20 C07D 231/26 C07D 233/70 C07D 401/04 C07D 401/10 C07D 401/12 C07D 401/14 C07D 403/04 C07D 403/10 C07D 403/12 C07D 405/04 C07D 405/10 C07D 405/12 C07D 405/14 C07D 409/04 C07D 409/12 C07D 413/10 C07D 413/12 C07D 413/14 C07D 417/12 C07F 5/025